Skip to content
NBlaz – Lifestyle
Author:
Harbour Biomed
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
July 23, 2026
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
July 15, 2026
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
June 28, 2026
Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D
June 15, 2026
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
June 14, 2026
Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
June 11, 2026
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
June 10, 2026
Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
June 10, 2026
First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
June 9, 2026
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
May 17, 2026
1
2
Next Page
→